To the best of my understanding it’s all at the discretion of the OTC - if they are satisfied that the company is demonstrably making “best efforts” and any concerns of misrepresentation or fraud are assuaged by a reasonable cursory assessment of practices. Then nothing changes. Other than the level of embarrassment to the company and it’s management team and the increasing further loss and continued erosion of retail and institutional investor confidence in the company and its leadership.
News 
Market Data 
Discover 
